Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIEKVIN
- Development stage
- Unknown
- Lead developer
- Institute Torlak
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
VIEKVIN is an equine-derived antivenom consisting of F(ab')2 antibody fragments, developed and manufactured by the Institute of Virology, Vaccines and Sera "Torlak" in Belgrade, Serbia. It is produced by immunizing horses with the freeze-dried venom of the long-nosed viper (*Vipera ammodytes*). The product is indicated for the treatment of envenomation following bites from venomous snakes of the *Vipera* genus, specifically *Vipera ammodytes* and *Vipera berus* (common European adder). It functions by neutralizing the toxic components of the venom, thereby providing passive immunity to the patient. Administration is typically via intramuscular or intravenous injection, with the latter reserved for severe cases of poisoning.
- Brand names
- VIEKVIN
- Other names
- VIEKVIN-Torlak-serum
02
Targets
ATX (Clostridium septicum alpha-toxin)LAAO (L-amino acid oxidase (Vipera ammodytes and Vipera berus))SVSP (Snake venom serine protease)SVMP (Snake venom metalloproteinase (Vipera ammodytes and Vipera berus))
Beyond the preview
Go deeper on VIEKVIN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIEKVIN.